Aptar’s Nasal Vaccine Delivery Solutions Featured in CastleVax Phase II Clinical Trial of an Intranasal COVID-19 Vaccine Candidate
AptarGroup, Inc. (ATR)
Last aptargroup, inc. earnings: 4/30 05:04 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.aptar.com
Company Research
Source: Business Wire
The use of LuerVax® and Spray Divider™ support Aptar’s commitment to advancing drug delivery and next-generation vaccine development, backed by comprehensive regulatory and technical expertise CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery and consumer product dosing, dispensing and protection technologies, announced that its innovative nasal vaccine delivery solutions, LuerVax® and Spray Divider™, are being utilized in CastleVax’s Phase II clinical trial of CVAX-01, a next-generation intranasal COVID-19 vaccine candidate. This milestone underscores Aptar Pharma’s commitment to advancing vaccine delivery technologies and supporting the development of novel immunization strategies. The Phase II study of CVAX-01 is assessing the safety, tolerability and systemic and mucosal immune response of CastleVax’s intranasal COVID-19 vaccine compared to an FDA-approved injectable mRNA vaccine. Around 200 U.S. adults, including high-risk indi
Show less
Read more
Impact Snapshot
Event Time:
ATR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATR alerts
High impacting AptarGroup, Inc. news events
Weekly update
A roundup of the hottest topics
ATR
News
- A Fresh Look At AptarGroup (ATR) Valuation After Recent Share Price Weakness [Yahoo! Finance]Yahoo! Finance
- Aptar's Intranasal Delivery System Used in Phase II Clinical Study for Investigational SPONTAN® Nasal Spray [Yahoo! Finance]Yahoo! Finance
- Aptar’s Intranasal Delivery System Used in Phase II Clinical Study for Investigational SPONTAN® Nasal SprayBusiness Wire
- New Strong Sell Stocks for March 9th [Yahoo! Finance Canada]Yahoo! Finance Canada
- Pharmaceutical Packaging Market Trends and Growth Projections to 2030 Featuring Profiles of AptarGroup, Amcor, SGD Pharma, West Pharmaceutical Services, SCHOTT Pharma and Other Key Players [Yahoo! Finance]Yahoo! Finance
ATR
Earnings
- 2/5/26 - Miss
ATR
Sec Filings
- 3/3/26 - Form 4
- 2/27/26 - Form 4
- 2/27/26 - Form 4
- ATR's page on the SEC website